XML 23 R16.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Related Party
 6 Months Ended
Jun. 30, 2024
Related Party Transactions [Abstract]  
Related Party
9.
Related Party

 

In May 2024, the Company entered into an agreement with the Friedreich’s Ataxia Research Alliance (FARA) to join the TRACK-FA Neuroimaging Consortium that includes pharmaceutical, biotechnology, academic and clinical partners. The consortium will conduct a natural history study designed to establish disease-specific neuroimaging biomarkers to track disease progression in the brain and spinal cord and provide a basis for utilizing these biomarkers in clinical trials. As an industry partner, the Company will help fund the study and contribute to the study design, research activities, and analysis. The Company will have access to all study data for use in its regulatory filings, as appropriate. The Company incurred $0.8M of costs related to the Track-FA program in the second quarter of 2024 and will fund future costs going forward. One of the Company’s Directors is also a director of FARA.